Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study. (4th May 2023)

• Record Type: Journal Article
• Authors: Maspero, Jorge F.; Cardona, Guido; Schonffeldt, Patricia; Tolcachier, Alberto; González-Diaz, Sandra N.; Yañez, Anahi; Galvao, Clovis E.; Msihid, Jerome; Gall, Rebecca; Siddiqui, Shahid; Rowe, Paul J.; Deniz, Yamo; Jacob-Nara, Juby A.; Djandji, Michel
• Is Part Of: Journal of asthma. Volume 60:Number 5(2023)
• Page Start: 981
• Page End: 990
• Publication Date: 2023-05-04
• Subjects: Biomarkers -- mechanisms -- quality of life -- treatment -- phenotypes; Asthma -- Periodicals; 616.238005
• DOI: 10.1080/02770903.2022.2115927
• Languages: English
• ISSNs: 0277-0903

Abstract

Abstract: Objective: While advances in asthma care have been made in Latin America, there is still a large unmet need in patients with uncontrolled asthma. This post hoc analysis of the QUEST study assessed safety and efficacy of dupilumab in the subgroup of patients enrolled in Latin American countries with a type 2 inflammatory asthma phenotype (blood eosinophils ≥ 150cells/µL or FeNO ≥25ppb). Methods: LIBERTY ASTHMA QUEST (NCT02414854) was a phase 3, multinational, randomized, double-blind, placebo-controlled study in patients with uncontrolled, moderate-to-severe asthma. Eligible patients ≥ 12 years of age were randomized in a 2:2:1:1 ratio to receive 52 weeks of add-on subcutaneous dupilumab 200 or 300 mg every 2 weeks or matched-volume placebos. Pre-specified co-primary efficacy endpoints were the annualized rate of severe exacerbations during the treatment period and the change from baseline in pre-bronchodilator FEV1 at treatment week 12. Asthma control, changes in asthma biomarker levels, and dupilumab safety were also evaluated. Results: 530 (27.9% of the overall QUEST population; dupilumab: 353, placebo: 177) Latin-American patients were recruited; 420 (79.2%) had a type 2 inflammatory asthma phenotype. Dupilumab vs placebo reduced the annualized rate of severe exacerbations by 52.7% ( P < 0.001) and increased pre-bronchodilator FEV1 at week 12 by 0.15 L ( P < 0.001), in the type 2 population. Safety was consistent with the known dupilumab safety profile. Conclusions: Consistent with the results in the overall population, dupilumab reduced the risk of severe asthma exacerbations and improved lung function in Latin American patients with uncontrolled, moderate-to-severe asthma and a type 2 phenotype.